Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
Top Cited Papers
- 1 March 2010
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (7), 1145-1153
- https://doi.org/10.1200/jco.2009.22.4725
Abstract
Cisplatin is a chemotherapeutic agent not used routinely for breast cancer treatment. As a DNA cross-linking agent, cisplatin may be effective treatment for hereditary BRCA1-mutated breast cancers. Because sporadic triple-negative breast cancer (TNBC) and BRCA1-associated breast cancer share features suggesting common pathogenesis, we conducted a neoadjuvant trial of cisplatin in TNBC and explored specific biomarkers to identify predictors of response. Twenty-eight women with stage II or III breast cancers lacking estrogen and progesterone receptors and HER2/Neu (TNBC) were enrolled and treated with four cycles of cisplatin at 75 mg/m2 every 21 days. After definitive surgery, patients received standard adjuvant chemotherapy and radiation therapy per their treating physicians. Clinical and pathologic treatment response were assessed, and pretreatment tumor samples were evaluated for selected biomarkers. Six (22%) of 28 patients achieved pathologic complete responses, including both patients with BRCA1 germline mutations;18 (64%) patients had a clinical complete or partial response. Fourteen (50%) patients showed good pathologic responses (Miller-Payne score of 3, 4, or 5), 10 had minor responses (Miller-Payne score of 1 or 2), and four (14%) progressed. All TNBCs clustered with reference basal-like tumors by hierarchical clustering. Factors associated with good cisplatin response include young age (P = .001), low BRCA1 mRNA expression (P = .03), BRCA1 promoter methylation (P = .04), p53 nonsense or frameshift mutations (P = .01), and a gene expression signature of E2F3 activation (P = .03). Single-agent cisplatin induced response in a subset of patients with TNBC. Decreased BRCA1 expression may identify subsets of TNBCs that are cisplatin sensitive. Other biomarkers show promise in predicting cisplatin response.Keywords
This publication has 49 references indexed in Scilit:
- Analyzing real-time PCR data by the comparative CT methodNature Protocols, 2008
- Abrogated Response to Cellular Stress Identifies DCIS Associated with Subsequent Tumor Events and Defines Basal-like Breast TumorsCancer Cell, 2007
- Pathologic complete remission rate after cisplatin-based primary chemotherapy in breast cancer: correlation with p63 expressionCancer Chemotherapy and Pharmacology, 2007
- Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancerProceedings of the National Academy of Sciences of the United States of America, 2007
- BRCA1 dysfunction in sporadic basal-like breast cancerOncogene, 2006
- A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancersNature Genetics, 2006
- Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast CancerJAMA, 2006
- Oncogenic pathway signatures in human cancers as a guide to targeted therapiesNature, 2005
- Hallmarks of 'BRCAness' in sporadic cancersNature Reviews Cancer, 2004
- Repeated observation of breast tumor subtypes in independent gene expression data setsProceedings of the National Academy of Sciences of the United States of America, 2003